LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

Home・Akcijų sąrašas・Coherus Oncology Inc

Coherus Oncology Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

1.44 -8.86

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

1.44

Max

1.46

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-278M -37M
Pardavimai	-438K 12M
P/E Sektoriaus vid.	3.509 49.888
Pelnas, tenkantis vienai akcijai	-0.25
Pelno marža	-300.041
Darbuotojai	145
EBITDA	7.9M -35M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+468.97% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-06

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-17M 242M
Ankstesnė atidarymo kaina	10.3
Ankstesnė uždarymo kaina	1.44

Naujienos nuotaikos

By Acuity

100%

318 / 344 reitingas Healthcare

Coherus Oncology Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-06-05 19:20; UTC

Pagrindinės rinkos jėgos

Meta Platforms Slips on Report of Plans for Multibillion-Dollar Offering to Fund AI Buildout

2026-06-06 08:20; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2026-06-06 08:20; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-06-06 04:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2026-06-06 00:14; UTC

Įsigijimai, susijungimai, perėmimai

4 Arm Execs Sold $26 Million in Stock, but They Missed a High -- Barrons.com

2026-06-05 21:27; UTC

Uždarbis

Carnage in Chip Stocks Hits Extra Hard in Top-Heavy Market -- WSJ

2026-06-05 20:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2026-06-05 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-06-05 20:20; UTC

Įsigijimai, susijungimai, perėmimai

Altice France Group Had Granted Initial Exclusivity Period to Consortium Until May 15, Which Was Then Extended to June 5

2026-06-05 20:19; UTC

Įsigijimai, susijungimai, perėmimai

Altice France Group, Bouygues Telecom, Free-iliad Group, Orange Exclusivity Period Extended by 48 Hours

2026-06-05 20:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2026-06-05 19:26; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-06-05 19:26; UTC

Rinkos pokalbiai

Hog Futures Tumble to Close Week -- Market Talk

2026-06-05 19:10; UTC

Rinkos pokalbiai

Canada's GDP Targets From AI-Related Spending Require Second Look -- Market Talk

2026-06-05 19:03; UTC

Rinkos pokalbiai

Oil Falls As Market Holds Out Hope for End to Conflict -- Market Talk

2026-06-05 18:59; UTC

Rinkos pokalbiai

U.S. Natural-Gas Futures Pull Back After Gains -- Market Talk

2026-06-05 18:47; UTC

Rinkos pokalbiai

Canada's Labor Market 'Retains Some Weakness' Despite Stellar May Report -- Market Talk

2026-06-05 18:34; UTC

Rinkos pokalbiai

Hyperliquid ETFs Have Inflows Despite Crypto Weakness -- Market Talk

2026-06-05 18:33; UTC

Įsigijimai, susijungimai, perėmimai

The U.S. Government Could Take a Stake in OpenAI. What That Means for Tech Stocks. -- Barrons.com

2026-06-05 17:50; UTC

Uždarbis

Lululemon Slumps on Earnings. Bargain Hunters Beware. -- Barrons.com

2026-06-05 17:27; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Rises for 6th Straight Week -- Market Talk

2026-06-05 16:48; UTC

Įsigijimai, susijungimai, perėmimai

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

2026-06-05 16:20; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2026-06-05 16:20; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-06-05 16:20; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-06-05 16:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2026-06-05 15:44; UTC

Įsigijimai, susijungimai, perėmimai

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

2026-06-05 15:26; UTC

Rinkos pokalbiai

Gold Down Nearly 3% On Rate Hike Concerns After U.S. Hiring Data -- Market Talk

2026-06-05 15:25; UTC

Uždarbis

Quantinuum Trades Below Offer Price. Why the Quantum Stock Is Sliding. -- Barrons.com

2026-06-05 15:16; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

Akcijų palyginimas

Kainos pokytis

Coherus Oncology Inc Prognozė

Kainos tikslas

By TipRanks

468.97% į viršų

12 mėnesių prognozė

Vidutinis 8.25 USD 468.97%

Aukščiausias 12 USD

Žemiausias 4 USD

Remiantis 5 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Coherus Oncology Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

5 ratings

Pirkti

Laikyti

Parduoti

Remiantis 5 analitikų, pateikusių Coherus Oncology Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

318 / 344 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Coherus Oncology Inc

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.